Core Viewpoint - Baixinan-B (02185) has seen a significant stock price increase of over 10%, currently up 13.5% at HKD 8.83, with a trading volume of HKD 106 million [1] Group 1: Market Developments - Boston Scientific is set to acquire SoniVie for a total price of USD 600 million, actively entering the RDN (Renal Denervation) market by March 2025 [1] - The American College of Cardiology and the American Heart Association updated hypertension treatment guidelines in August, incorporating RDN as a Class IIb recommendation [1] - The Centers for Medicare & Medicaid Services (CMS) proposed a national coverage decision for RDN in July, which, if approved, will significantly accelerate clinical adoption [1] Group 2: Industry Insights - RDN is a new therapeutic device for uncontrolled and resistant hypertension, with the Chinese RDN market expected to exceed RMB 10 billion by 2032 according to Zhi Shi Consulting [1] - Baixinan's Iberis RDN system is the only globally approved device that offers both transradial (TRA) and transfemoral access for RDN, providing a significant first-mover advantage [1] - Strategic partnerships have been established with Yuan Da Health and other international companies to accelerate commercialization, with Germany and France already including Iberis RDN in their healthcare coverage [1]

Core Viewpoint - Baixinan-B (02185) experienced a significant stock price increase, rising nearly 15% towards the end of trading, with a current price of 6.14 HKD and a trading volume of 16.9358 million HKD, driven by recent developments in its partnership with Bluestar Medical [1] Company Developments - Bluestar Medical announced a collaboration with Baixinan for the Iberis™ multi-polar renal denervation (RDN) system, leveraging its platform capabilities and industry reputation to expand into international markets [1] - The Iberis™ RDN system has already been commercialized in Germany, Spain, and Italy, and has recently received approval for clinical use in Singapore [1] Market Potential - According to Zhi Shi Consulting, the annual market size for RDN in China is expected to exceed 10 billion RMB by 2032, indicating significant growth potential in this sector [1] - Huafu Securities highlighted that Baixinan's Iberis® RDN system is the only one globally approved for both transradial (TRA) and transfemoral access, showcasing a notable first-mover advantage [1] Strategic Partnerships - Baixinan has formed strategic collaborations with Yuanda Health and various international partners through Bluestar Medical, which is expected to accelerate its commercialization efforts [1] - The inclusion of the Iberis® RDN system in the healthcare insurance systems of Germany and France is anticipated to further enhance Baixinan's market position [1]